eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines Updated for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. These NCCN Guidelines^® are currently available as Version 3.2023.

Link directly to the Updates section of the NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Global

• Footnote "Covalent (irreversible) BTK inhibitors" added to acalabrutinib, ibrutinib, and zanubrutinib.

CSLL-D 2 of 6

• CLL/SLL without del(17p)/TP53 mutation,
  • Second-line or Third-line Therapy: "Pirtobrutinib (resistance or intolerance to prior covalent BTKi therapy)" added as a category 2A, Useful in certain circumstances regimen.
  • Therapy for Relapsed or Refractory Disease After Prior BTKi-and Venetoclax-Based Regimens: "Pirtobrutinib (if not previously used)" added as a category 2A, other recommended regimen.
  • Corresponding footnote p added: Please refer to package insert for full prescribing information, dose modifications, and monitoring for adverse reactions: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216059Orig1s000Corrected_lbl.pdf. (Also for CSLL-D 3 of 6)

CSLL-D 3 of 6

• CLL/SLL with del(17p)/TP53 mutation,
  • Second-line or Third-line Therapy: "Pirtobrutinib (resistance or intolerance to prior covalent BTKi therapy)" added as a category 2A, Useful in certain circumstances regimen.
  • Therapy for Relapsed or Refractory Disease After Prior BTKi-and Venetoclax-Based Regimens: "Pirtobrutinib (if not previously used)" added as a category 2A, other recommended regimen.

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: https://private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works. 

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.